Instituto Valenciano de Infertilidad, IVI VALENCIA
ivi.esTotal trials
72
Active
5
Phase 3
9
Total enrollment
13,675
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Corifolitropin Alfa | — | — | — | — | — | 1 | |
| Folitropin Beta | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
Top conditions
- Infertility11
- Infertility, Female10
- Ovarian Stimulation3
- Ovarian Hyperstimulation Syndrome3
- Reproductive Sterility3
- Sperm Selection3
- Oocyte Maturation2
- Endometrial Receptivity2
Frequently asked questions about Instituto Valenciano de Infertilidad, IVI VALENCIA
- How many clinical trials does Instituto Valenciano de Infertilidad, IVI VALENCIA have on ClinicalTrials.gov?
- Instituto Valenciano de Infertilidad, IVI VALENCIA is listed as the lead sponsor on 72 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Instituto Valenciano de Infertilidad, IVI VALENCIA's trials are in Phase 3?
- 9 of Instituto Valenciano de Infertilidad, IVI VALENCIA's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Instituto Valenciano de Infertilidad, IVI VALENCIA focus on?
- Instituto Valenciano de Infertilidad, IVI VALENCIA's most-studied conditions on ClinicalTrials.gov are Infertility, Infertility, Female, Ovarian Stimulation, Ovarian Hyperstimulation Syndrome, Reproductive Sterility.
- When are Instituto Valenciano de Infertilidad, IVI VALENCIA's next clinical trial readouts?
- Instituto Valenciano de Infertilidad, IVI VALENCIA has 1 upcoming primary-completion readout tracked here; the soonest is “Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)”, expected around 2025-12-31.